
Lisa Cusaac never planned on being an oncology nurse. However, 25 years later she has spent her entire career providing care for patients with cancer and being an Oncology Nurse Champion.

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Lisa Cusaac never planned on being an oncology nurse. However, 25 years later she has spent her entire career providing care for patients with cancer and being an Oncology Nurse Champion.

The combination of ficlatuzumab and chemotherapy demonstrated some promising results in a small group of patients with relapsed/refractory acute myeloid leukemia.

A trial evaluating melflufen in myeloma met its primary end point of progression free survival in the phase 3 OCEAN trial; however, overall survival was in favor of pomalidomide.

The FDA has offered support and encouragement for the development of paclitaxel plus encequidar.

The Food and Drug Administration has approved pembrolizumab for the treatment of patients with a locally advanced form of skin cancer.

Out of 30 patients, 16 demonstrated significant pathological responses and 8 achieved a complete pathological response.

A retrospective cohort study found that convalescent plasma treatment resulted in a meaningful improvement in the 30-day mortality rate for patients with hematologic cancer and COVID-19.

ASCO updated its guidelines following a presentation of the OlympiA trial presented at its 2021 Annual Meeting.

A presentation at the 2021 American Society of Clinical Oncology Meeting demonstrated that the use of electronic patient-reported outcomes in community oncology centers improved symptom-management.

Nearly half of patients with gynecologic cancer reported financial distress, or financial toxicity, new study says.

“Looking at how the movement toward videoconferencing visits during the COVID-19 pandemic affects the nurse-patient relationship and the capacity to maintain high quality, supportive cancer care is essential…”

A Texas study revealed that the implementation of electronic patient management solutions resulted in reduced call back times for symptom-related calls as well as reduced hospitalizations.

The FDA granted a priority review for a Biologics License Application (BLA) to bastilimab for the treatment of recurrent or metastatic cervical cancer.